Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Tricuspid regurgitation pathophysiology

Introduction

Overview

Overview

Tricuspid regurgitation (TR) results in a retrograde flow of blood into the right atrium due to the incompetent tricuspid valve. The pathophysiology of TR depends on whether TR is primary or secondary. Primary TR results from an organic abnormality in one or more parts of the tricuspid valve, such as the leaflets, chordae tendineae, or papillary muscles. Secondary TR commonly results from hemodynamic and structural changes in the right ventricle and tricuspid valve apparatus secondary to left-sided heart pathology and/or pulmonary hypertension. Tricuspid annular dilation is the most important factor in the pathophysiology of secondary TR. In addition, tethering of the leaflets and inadequate leaflet coaptation also contribute to secondary TR.

Pathophysiology

Pathophysiology

The Tricuspid Valve Apparatus

The tricuspid valve apparatus includes the following structures:[1][2][3][4][5][6][1]

Pathogenesis

Primary Tricuspid Regurgitation

Secondary Tricuspid Regurgitation

  • The most common cause of tricuspid regurgitation in adults is secondary / functional which can be defined as without anatomical anomalies and normal leaflet and chords structure.
  • More than 80% of the cases of TR seen in clinical practice is secondary(functional) in nature and related to tricuspid annular dilatation and leaflet tethering in the setting of right ventricular remodeling caused by pressure or volume overload (or both), myocardial infarction, or trauma.[6][18]
  • In secondary TR, progressive tricuspid annular dilation and right ventricular remodeling lead to worsening leaflet malcoaptation. As regurgitation severity increases, volume overload of the right atrium and ventricle further accelerates chamber dilation, creating a self-perpetuating cycle of disease progression.[19]
  • Ventricular secondary TR is generally associated with more advanced right ventricular dysfunction and worse prognosis than atrial secondary TR.[19]
  • The underlying pathophysiology of secondary TR involves the following changes:[1][20][21][22][23]
  • In summary, tricuspid annular dilation is the most important factor in the pathophysiology of secondary TR, though tethering of the leaflets and inadequate leaflet coaptation also contribute to secondary TR.[1]
References

References

  1. ↑ 1.0 1.1 1.2 1.3 Taramasso M, Vanermen H, Maisano F, Guidotti A, La Canna G, Alfieri O (2012). “The growing clinical importance of secondary tricuspid regurgitation”. J Am Coll Cardiol. 59 (8): 703–10. doi:10.1016/j.jacc.2011.09.069. PMIDΒ 22340261.
  2. ↑ Unger P, Clavel MA, Lindman BR, Mathieu P, Pibarot P (July 2016). “Pathophysiology and management of multivalvular disease”. Nat Rev Cardiol. 13 (7): 429–40. doi:10.1038/nrcardio.2016.57. PMCΒ 5129845. PMIDΒ 27121305.
  3. ↑ Tornos Mas P, RodrΓ­guez-Palomares JF, Antunes MJ (November 2015). “Secondary tricuspid valve regurgitation: a forgotten entity”. Heart. 101 (22): 1840–8. doi:10.1136/heartjnl-2014-307252. PMCΒ 4680164. PMIDΒ 26503944.
  4. ↑ Anyanwu AC (2010). “Functional tricuspid regurgitation: introduction”. Semin. Thorac. Cardiovasc. Surg. 22 (1): 67–8. doi:10.1053/j.semtcvs.2010.06.001. PMIDΒ 20813319.
  5. ↑ 5.0 5.1 Rogers JH, Bolling SF (2009). “The tricuspid valve: current perspective and evolving management of tricuspid regurgitation”. Circulation. 119 (20): 2718–25. doi:10.1161/CIRCULATIONAHA.108.842773. PMIDΒ 19470900.
  6. ↑ 6.0 6.1 RodΓ©s-Cabau J, Taramasso M, O’Gara PT (2016). “Diagnosis and treatment of tricuspid valve disease: current and future perspectives”. Lancet. 388 (10058): 2431–2442. doi:10.1016/S0140-6736(16)00740-6. PMIDΒ 27048553 PMID: 27048553 Check |pmid= value (help).
  7. ↑ Waller BF (1987). “Etiology of pure tricuspid regurgitation”. Cardiovasc Clin. 17 (2): 53–95. PMIDΒ 3536106.
  8. ↑ Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC; et al. (2009). “Importance of venous congestion for worsening of renal function in advanced decompensated heart failure”. J Am Coll Cardiol. 53 (7): 589–596. doi:10.1016/j.jacc.2008.05.068. PMCΒ 2856960. PMIDΒ 19215833.
  9. ↑ Maeder MT, Holst DP, Kaye DM (2008). “Tricuspid regurgitation contributes to renal dysfunction in patients with heart failure”. J Card Fail. 14 (10): 824–30. doi:10.1016/j.cardfail.2008.07.236. PMIDΒ 19041045.
  10. ↑ Mutlak D, Lessick J, Reisner SA, Aronson D, Dabbah S, Agmon Y (2007). “Echocardiography-based spectrum of severe tricuspid regurgitation: the frequency of apparently idiopathic tricuspid regurgitation”. J Am Soc Echocardiogr. 20 (4): 405–8. doi:10.1016/j.echo.2006.09.013. PMIDΒ 17400120.
  11. ↑ Adler DS (May 2017). “Non-functional tricuspid valve disease”. Ann Cardiothorac Surg. 6 (3): 204–213. doi:10.21037/acs.2017.04.04. PMCΒ 5494423. PMIDΒ 28706863.
  12. ↑ Shah PM, Raney AA (2008). “Tricuspid valve disease”. Curr Probl Cardiol. 33 (2): 47–84. doi:10.1016/j.cpcardiol.2007.10.004. PMIDΒ 18222317.
  13. ↑ Shiran A, Sagie A (2009). “Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism, and management”. J Am Coll Cardiol. 53 (5): 401–8. doi:10.1016/j.jacc.2008.09.048. PMIDΒ 19179197.
  14. ↑ Waller BF, Moriarty AT, Eble JN, Davey DM, Hawley DA, Pless JE (1986). “Etiology of pure tricuspid regurgitation based on anular circumference and leaflet area: analysis of 45 necropsy patients with clinical and morphologic evidence of pure tricuspid regurgitation”. J Am Coll Cardiol. 7 (5): 1063–74. doi:10.1016/s0735-1097(86)80224-8. PMIDΒ 3958362.
  15. ↑ Waller BF, Moriarty AT, Eble JN, Davey DM, Hawley DA, Pless JE (1986) Etiology of pure tricuspid regurgitation based on anular circumference and leaflet area: analysis of 45 necropsy patients with clinical and morphologic evidence of pure tricuspid regurgitation. J Am Coll Cardiol 7 (5):1063-74. DOI:10.1016/s0735-1097(86)80224-8 PMID: 3958362
  16. ↑ Baseman DG, O’Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB (2004). “Pergolide use in Parkinson disease is associated with cardiac valve regurgitation”. Neurology. 63 (2): 301–4. doi:10.1212/01.wnl.0000129842.49926.07. PMIDΒ 15277624.
  17. ↑ Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE (2002). “Valvular heart disease in patients taking pergolide”. Mayo Clin Proc. 77 (12): 1280–6. doi:10.4065/77.12.1280. PMIDΒ 12479512.
  18. ↑ Sagie A, Schwammenthal E, Padial LR, Vazquez de Prada JA, Weyman AE, Levine RA (1994). “Determinants of functional tricuspid regurgitation in incomplete tricuspid valve closure: Doppler color flow study of 109 patients”. J Am Coll Cardiol. 24 (2): 446–53. doi:10.1016/0735-1097(94)90302-6. PMIDΒ 8034882.
  19. ↑ 19.0 19.1 Hahn RT (May 2023). “Tricuspid Regurgitation”. N Engl J Med. 388 (20): 1876–1891. doi:10.1056/NEJMra2216709. PMIDΒ 37195943 Check |pmid= value (help).
  20. ↑ Mikami T, Kudo T, Sakurai N, Sakamoto S, Tanabe Y, Yasuda H (January 1984). “Mechanisms for development of functional tricuspid regurgitation determined by pulsed Doppler and two-dimensional echocardiography”. Am. J. Cardiol. 53 (1): 160–3. doi:10.1016/0002-9149(84)90702-1. PMIDΒ 6691254.
  21. ↑ Dreyfus GD, Martin RP, Chan KM, Dulguerov F, Alexandrescu C (June 2015). “Functional tricuspid regurgitation: a need to revise our understanding”. J. Am. Coll. Cardiol. 65 (21): 2331–6. doi:10.1016/j.jacc.2015.04.011. PMIDΒ 26022823.
  22. ↑ Di Mauro M, Bezante GP, Di Baldassarre A, Clemente D, Cardinali A, Acitelli A, Salerni S, Penco M, Calafiore AM, Gallina S (September 2013). “Functional tricuspid regurgitation: an underestimated issue”. Int. J. Cardiol. 168 (2): 707–15. doi:10.1016/j.ijcard.2013.04.043. PMIDΒ 23647591.
  23. ↑ Nemoto N, Lesser JR, Pedersen WR, Sorajja P, Spinner E, Garberich RF, Vock DM, Schwartz RS (August 2015). “Pathogenic structural heart changes in early tricuspid regurgitation”. J. Thorac. Cardiovasc. Surg. 150 (2): 323–30. doi:10.1016/j.jtcvs.2015.05.009. PMIDΒ 26050849.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Β ; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]Β ; Fatimo Biobaku M.B.B.S [3]Β ; Vamsikrishna Gunnam M.B.B.S [4]Β ; Basir Gill, M.B.B.S, M.D.[5]